Malnutrition clinical trials at UCLA
2 research studies open to eligible people
Occurrence of EFAD in Pediatric Patients with PNAC Who Require More Than Eight Weeks of Omegaven Treatment
open to eligible people ages up to 17 years
This study will demonstrate safety in pediatric patients with Parenteral Nutrition-Associated Cholestasis treated with Omegaven®, which is indicated as a source of calories and fatty acids in this patient population
Los Angeles, California and other locations
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
open to eligible people ages 18 years and up
This clinical trial compares the effect of malnutrition screening and dietary intervention to standard nutrition care on patients with pancreatic cancer that cannot be removed by surgery (unresectable). Fewer than 20% of patients diagnosed with unresectable pancreatic cancer do not survive one year after diagnosis so treatment often focuses on improving quality of life. Many patients experience increasing pain, nausea, vomiting, loss of appetite, weight loss and weakness. Behavioral interventions use techniques to help patients change the way they react to environmental triggers that may cause a negative reaction. Screening for inadequate nutrition (malnutrition) and providing weekly nutritional support may be effective methods to improve nutritional status and improve overall quality of life for patients with unresectable pancreatic cancer.
Los Angeles, California
Our lead scientists for Malnutrition research studies include ZhaoPing Li Kara L. Calkins, MD.
Last updated: